Søgeord (pseudomonas) valgt.
13 emner vises.
1
Pseudomonas Infection Outbreak Associated with a Hotel Swimming Pool - Maine, March 2023
Morbidity and Mortality Weekly Report (MMWR), 19.01.2024
Tilføjet 19.01.2024
This report describes an outbreak of Pseudomonas infections associated with swimming in a hotel pool.
Læs mere
2
Impact of the COVID-19 pandemic on prevalence of highly resistant microorganisms in hospitalised patients in the Netherlands, March 2020 to August 2022
Wieke Altorf-van der Kuil, Cornelia CH Wielders, Romy D Zwittink, Sabine C de Greeff, Dave A. Dongelmans, Ed J Kuijper, Daan W Notermans, Annelot F Schoffelen and on behalf of the study collaborators ISIS-AR study group
Eurosurveillance latest updates, 15.12.2023
Tilføjet 15.12.2023
BackgroundThe COVID-19 pandemic resulted in adaptation in infection control measures, increased patient transfer, high occupancy of intensive cares, downscaling of non-urgent medical procedures and decreased travelling. AimTo gain insight in the influence of these changes on antimicrobial resistance (AMR) prevalence in the Netherlands, a country with a low AMR prevalence, we estimated changes in demographics and prevalence of six highly resistant microorganisms (HRMO) in hospitalised patients in the Netherlands during COVID-19 waves (March–June 2020, October 2020–June 2021, October 2021–May 2022 and June–August 2022) and interwaves (July–September 2020 and July–September 2021) compared with pre-COVID-19 (March 2019–February 2020). MethodsWe investigated data on routine bacteriology cultures of hospitalised patients, obtained from 37 clinical microbiological laboratories participating in the national AMR surveillance. Demographic characteristics and HRMO prevalence were calculated as proportions and rates per 10,000 hospital admissions. ResultsAlthough no significant persistent changes in HRMO prevalence were detected, some relevant non-significant patterns were recognised in intensive care units. Compared with pre-COVID-19 we found a tendency towards higher prevalence of meticillin-resistant Staphylococcus aureus during waves and lower prevalence of multidrug-resistant Pseudomonas aeruginosa during interwaves. Additionally, during the first three waves, we observed significantly higher proportions and rates of cultures with Enterococcus faecium (pooled 10% vs 6% and 240 vs 120 per 10,000 admissions) and coagulase-negative Staphylococci (pooled 21% vs 14% and 500 vs 252 per 10,000 admissions) compared with pre-COVID-19. ConclusionWe observed no substantial changes in HRMO prevalence in hospitalised patients during the COVID-19 pandemic.
Læs mere
3
Healthcare-associated infections by multidrug-resistant bacteria in Andalusia, Spain, 2014 to 2021
Nicolás Francisco Fernández-Martínez, Mario Rivera-Izquierdo, Rocío Ortiz-González-Serna, Virginia Martínez-Ruiz, Pablo Lardelli-Claret, Adrián Hugo Aginagalde-Llorente, María del Carmen Valero-Ubierna, María Auxiliadora Vergara-Díaz and Nicola Lorusso
Eurosurveillance latest updates, 29.09.2023
Tilføjet 29.09.2023
BackgroundMultidrug-resistant (MDR) bacteria are among chief causes of healthcare-associated infections (HAIs). In Spain, studies addressing multidrug resistance based on epidemiological surveillance systems are lacking. AimIn this observational study, cases of HAIs by MDR bacteria notified to the epidemiological surveillance system of Andalusia, Spain, between 2014−2021, were investigated. Notified cases and their spatiotemporal distribution were described, with a focus on social determinants of health (SDoH). MethodsNew cases during the study period of HAIs caused by extended-spectrum β-lactamase (ESBL)-/carbapenemase-producing Enterobacterales, MDR Acinectobacter baumannii, MDR Pseudomonas aeruginosa or meticillin resistant Staphylococcus aureus were considered. Among others, notification variables included sex and age, while socio-economic variables comprised several SDoH. Cases’ spatial distribution across municipalities was assessed. The smooth standardised incidence ratio (sSIR) was obtained using a Bayesian spatial model. Association between municipalities’ sSIR level and SDoH was evaluated by bivariate analysis. ResultsIn total, 6,389 cases with a median age of 68 years were notified; 61.4% were men (n = 3,921). The most frequent MDR bacteria were ESBL-producing Enterobacterales (2,812/6,389; 44.0%); the main agent was Klebsiella spp. (2,956/6,389; 46.3%). Between 2014 and 2021 case numbers appeared to increase. Overall, up to 15-fold differences in sSIR between municipalities were observed. In bivariate analysis, there appeared to be an association between municipalities’ sSIR level and deprivation (p = 0.003). ConclusionThis study indicates that social factors should be considered when investigating HAIs by MDR bacteria. The case incidence heterogeneity between Andalusian municipalities might be explained by SDoH, but also possibly by under-notification. Automatising reporting may address the latter.
Læs mere
4
Cluster of Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa Among Patients in an Adult Intensive Care Unit - Idaho, 2021-2022
Morbidity and Mortality Weekly Report (MMWR), 4.08.2023
Tilføjet 4.08.2023
This report describes an investigation of two cases of carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa among ICU patients who stayed in the same hospital room.
Læs mere
5
Communicable disease threats report, 21-27 May 2023, week 21
ECDC
ECDC COVID-19 updates, 27.05.2023
Tilføjet 27.05.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 21-27 May 2023 May 2023 and includes updates on COVID-19, influenza, Marburg virus disease, poliomyelitis, extensively drug-resistant Pseudomonas aeruginosa, and suspected fungal meningitis.
Læs mere
6
Communicable disease threats report, 21-27 May 2023, week 21
ECDC
ECDC Communicable Disease Threats Report, 26.05.2023
Tilføjet 26.05.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 21-27 May 2023 May 2023 and includes updates on COVID-19, influenza, Marburg virus disease, poliomyelitis, extensively drug-resistant Pseudomonas aeruginosa, and suspected fungal meningitis.
Læs mere
7
Clinical epidemiology and case fatality due to antimicrobial resistance in Germany: a systematic review and meta-analysis, 1 January 2010 to 31 December 2021
Maria Rödenbeck, Olaniyi Ayobami, Tim Eckmanns, Mathias W Pletz, Jutta Bleidorn and Robby Markwart
Eurosurveillance latest updates, 19.05.2023
Tilføjet 19.05.2023
BackgroundAntimicrobial resistance (AMR) is of public health concern worldwide. AimWe aimed to summarise the German AMR situation for clinicians and microbiologists. MethodsWe conducted a systematic review and meta-analysis of 60 published studies and data from the German Antibiotic-Resistance-Surveillance (ARS). Primary outcomes were AMR proportions in bacterial isolates from infected patients in Germany (2016–2021) and the case fatality rates (2010–2021). Random and fixed (common) effect models were used to calculate pooled proportions and pooled case fatality odds ratios, respectively. ResultsThe pooled proportion of meticillin resistance in Staphylococcus aureus infections (MRSA) was 7.9% with a declining trend between 2014 and 2020 (odds ratio (OR) = 0.89; 95% CI: 0.886–0.891; p
Læs mere
8
Communicable disease threats report 19 - 25 March, Week 12
ECDC
ECDC Communicable Disease Threats Report, 11.04.2023
Tilføjet 11.04.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19-25 March 2023 and includes updates on Marburg virus disease, iatrogenic botulism, COVID-19, Influenza, Group A streptococcal infection, cholera, poliomyelitis, measles, and extensively drug-resistant Pseudomonas aeruginosa.
Læs mere
9
PRO/EDR> Pseudomonas aeruginosa - USA (05): India-made/XDR/contam eye drops, RFI
ProMED, 6.04.2023
Tilføjet 6.04.2023
P. aeruginosa -- United StatesFederal inspectors found dozens of issues at an eye drops manufacturer now linked to a fatal outbreak of drug-resistant bacteria, inspection records released by the Food and Drug Administration show, ranging from dirty equipment and clothing to missing safeguards and procedures.The FDA's findings were detailed in citations issued to Indian manufacturer Global Pharma Healthcare Pvt Ltd after an inspection from 20 Feb through 2 Mar 2023. This appears to have been the company's 1st visit from
Læs mere
10
Communicable disease threats report 19 - 25 March, Week 12
ECDC COVID-19 updates, 25.03.2023
Tilføjet 25.03.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19-25 March 2023 and includes updates on Marburg virus disease, iatrogenic botulism, COVID-19, Influenza, Group A streptococcal infection, cholera, poliomyelitis, measles, and extensively drug-resistant Pseudomonas aeruginosa.
Læs mere
11
PRO/EDR> Pseudomonas aeruginosa - USA (04): India-made/XDR/contam. eye drops, more cases
ProMED, 18.03.2023
Tilføjet 18.03.2023
P. aeruginosa -- United States'As of 14 Mar 2023, CDC, in partnership with state and local health departments, identified 68 patients in 16 states (CA, CO, CT, FL, IL, NC, NJ, NM, NY, NV, PA, SD, TX, UT, WA, WI) with VIM-GES-CRPA, a rare strain of extensively drug-resistant _P. aeruginosa_. Thirty-seven patients were linked to 4 healthcare facility clusters. One person has died and there have been 8 reports of vision loss and 4 reports of enucleation (surgical removal of eyeball). Dates of specimen collection were from May
Læs mere
12
PRO/EDR> Pseudomonas aeruginosa - USA (03): India made, contaminated eye drops, recall
ProMED, 8.02.2023
Tilføjet 8.02.2023
P. aeruginosa -- United StatesThe Food and Drug Administration (FDA) has warned against using 'Artificial Tears' eye drops produced by a Tamil Nadu-based firm after an outbreak of drug-resistant infections was linked to the drug in the USA. This is the 3rd such controversy involving an Indian pharma company.Another controversy has hit India's pharmaceutical industry as the United States warned that an eye drop manufactured by a Tamil Nadu-based firm has caused an outbreak of the drug-resistant bacterium _Pseudomonas
Læs mere
13
PRO/EDR> Pseudomonas aeruginosa - USA (02): contaminated eye drops, XDR, CDC, recall
ProMED, 4.02.2023
Tilføjet 4.02.2023
P. aeruginosa -- United StatesPatients should stop using EzriCare Artificial Tears pending additional information and guidance from CDC and FDA. If patients were advised to use EzriCare Artificial Tears by their healthcare provider, they should follow up with their healthcare provider for recommendations about alternative treatment options. Patients who have used EzriCare preservative-free artificial tears and who have signs or symptoms of an eye infection should seek medical care immediately. At this time, there is no
Læs mere